Skip to main content

Table 3 Distribution of dopamine replacement therapy according to patients’ functional requirements a

From: The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study

Function level

Therapy

2007

2011

High

DA monotherapy, n (%)

6 (33%)

14 (59%)b

Daily LD equivalents, mg (mean ± SD)

350 ± 57

335 ± 57

 

LD monotherapy, n (%)

3 (17%)

2 (8%)

Daily dose, mg (mean ± SD)

315 ± 33

325 ± 15

 

DA + LD combined therapy, n (%)

9 (50%)

8 (33%)

Total daily LD equivalents, mg (mean ± SD)

400 ± 52

415 ± 35

Moderate

DA monotherapy, n (%)

5 (25%)

10 (53%)b

Daily LD equivalents, mg (mean ± SD)

250 ± 25

325 ± 33b

 

LD monotherapy, n (%)

7 (35%)

2 (10%)b

Daily dose, mg (mean ± SD)

280 ± 25

275 ± 12

 

DA + LD combined therapy, n (%)

8 (40%)

7 (37%)

Total daily LD equivalents, mg (mean ± SD)

324 ± 34

330 ± 35

Low

DA monotherapy, n (%)

3 (17%)

4 (14%)

Daily LD equivalents, mg (mean ± SD)

255 ± 15

261 ± 27

 

LD monotherapy, n (%)

9 (50%)

12 (41%)

Daily dose, mg (mean ± SD)

250 ± 25

230 ± 32

 

DA + LD combined therapy, n (%)

6 (33%)

13 (45%)

Daily LD equivalents, mg (mean ± SD)

289 ± 21

277 ± 27

  1. aDA, dopamine agonist; LD, levodopa. bP < 0.01 compared with 2007 by χ2 test or unpaired Student’s t-test. See Methods Section for details.